NCT06223828 Azithromycin for Critical Asthma - Pediatrics
| NCT ID | NCT06223828 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Johns Hopkins All Children's Hospital |
| Condition | Pediatric Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-04-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2024-04-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Eligibility Criteria
Inclusion criteria * Age 3-17 years * Admission to the PICU * Primary diagnosis of critical asthma * Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy * Prescription for intravenous systemic corticosteroids Exclusion criteria * Critical Congenital Heart Disease Unrepaired * Tracheostomy Dependence at Admission * Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication * Past Medical History of Prolonged QT Syndrome or Arrhythmias * Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
Contact & Investigator
Anthony A Sochet, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins All Children's Hospital
Frequently Asked Questions
Who can join the NCT06223828 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 17 Years, studying Pediatric Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06223828 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06223828 currently recruiting?
Yes, NCT06223828 is actively recruiting participants. Contact the research team at Sochet@jhmi.edu for enrollment information.
Where is the NCT06223828 trial being conducted?
This trial is being conducted at St. Petersburg, United States.
Who is sponsoring the NCT06223828 clinical trial?
NCT06223828 is sponsored by Johns Hopkins All Children's Hospital. The principal investigator is Anthony A Sochet, MD at Johns Hopkins All Children's Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.